Key Finding: Sartorius Unveils Next-Generation Lab Balance ‘Cubis III’ with Enhanced Data Integrity and 21 CFR Part 11 Compliance
Sartorius has announced the introduction of ‘Cubis III,’ the latest generation of laboratory balances joining its portfolio of lab equipment. This innovative product is engineered to meet the demands of today’s digitalized laboratory environments, providing direct embedded connectivity for measurement data to digital systems. This eliminates the need for complex middleware traditionally required, leading to substantial reductions in operational costs and system complexity.
Technical & Clinical Details: Advanced Connectivity and Regulatory Compliance Features
- Direct Digital Integration: Cubis III features the capability to directly transfer data generated by the balance to Laboratory Information Management Systems (LIMS), Electronic Lab Notebooks (ELN), or other digital record systems. This seamless connectivity eliminates the risk of data entry errors and reduces the time spent on manual data transcription.
- Middleware-Free Operation: Many traditional laboratory instruments required expensive and complex middleware for data exchange between multiple systems. Cubis III obviates this intermediate layer, significantly reducing the effort and cost associated with system setup, maintenance, and validation.
- 21 CFR Part 11 Compliance Support: Designed with operations in highly regulated environments such as the pharmaceutical and biotechnology industries in mind, Cubis III supports data management functions compliant with the FDA’s 21 CFR Part 11. This includes features such as audit trails, electronic signatures, and mechanisms to ensure data protection and integrity, guaranteeing the reliability and completeness of data.
- User Interface and Usability: Equipped with an intuitive and customizable user interface, Cubis III offers flexible operability to suit various applications. This enables researchers to work efficiently and enhance the reliability of their measurements.
Background & Industry Context: The Importance of Data Integrity and Digitalization Drive
In the pharmaceutical and biotechnology sectors, data integrity stands as one of the most critical requirements throughout the entire drug development lifecycle, from R&D to manufacturing and quality control. Regulatory authorities strongly advocate for adherence to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) to ensure the accuracy, completeness, consistency, and security of data. Advanced lab instruments like Cubis III play an indispensable role in meeting these demands and driving laboratory digitalization and automation.
Future Outlook: Enabling the Smart Lab and Efficient Drug Development
The introduction of Cubis III marks a significant step towards realizing the Smart Lab vision. Direct digital integration of lab equipment not only streamlines data management but also enables faster decision-making, process optimization, and smoother regulatory reporting. This is expected to shorten the drug development cycle, allowing high-quality products to reach patients more quickly. Sartorius is poised to continue leading the evolution of the bioprocess industry by providing innovative solutions that address digitalization and data integrity needs.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments